In 2009, China's pharmaceutical import and export totaled over 50 billion US dollars

In 2009, the overall operation of China's pharmaceutical foreign trade was good, and the import and export of pharmaceutical and health care products rose against the trend The total import and export reached 53.1 billion US dollars, a new record The annual operation was basically stable in 2009, and China's Pharmaceutical Foreign Trade moved forward in the fluctuation, with the import and export volume of pharmaceutical and health care products reaching 53.15 billion US dollars, up 9.8% year on year Among them, imports reached US $20.236 billion, up 21.5% year on year; exports reached US $32.91 billion, up 3.7% year on year The surplus of foreign trade in medicine was 12.67 billion US dollars, down 16.6% year on year In terms of export, the total export volume of traditional Chinese medicine products is US $1.462 billion, up 11.72% year on year, accounting for 4.44% of the total export volume of all medical insurance products in China; the export volume of Western medicine products is US $19.2 billion, down 0.8% year on year, accounting for 58.4% of the total export volume of all medical insurance products; the export volume of medical equipment products is US $12.25 billion, up 10.64% year on year, accounting for the total export volume of all medical insurance products The proportion of is 37% In terms of imports, the imports of traditional Chinese medicine products reached 542 million US dollars, a year-on-year increase of 22.14%, accounting for 2.68% of the total imports; the imports of Western medicine products reached 13.59 billion US dollars, a year-on-year increase of 23.6%, accounting for 67.3% of the total exports of all medical insurance products; the imports of medical equipment products reached 6.1 billion US dollars, a year-on-year increase of 17%, accounting for 30.2% of the total exports of all medical insurance products From the perspective of classified products, the import and export trade of biochemical drugs, medical excipients and plant extracts was active and increased significantly Among them, biochemical drug export reached US $1.446 billion, a year-on-year increase of 60.22%, ranking first in export growth; import reached US $1.019 billion, a year-on-year increase of 31.8% The export of dental equipment and materials reached 248 million US dollars, up 23.62% year on year, and the import reached 126 million US dollars, up 27.39% year on year The export of plant extracts reached 655 million US dollars, a year-on-year increase of 23.69%; the import of plant extracts reached 162 million US dollars, a year-on-year increase of 129.19%, ranking first in the increase of imports In addition, the performance of medical dressings and Western patent medicines is not bad The export of the former totaled 4.136 billion US dollars, an increase of 32.85% year-on-year, ranking first in the export of medical devices; the import of Western patent medicines increased 22.2% year-on-year, to 4.858 billion US dollars, ranking second in the import volume, second only to Western raw materials In addition, the operation of traditional bulk medical products such as hospital diagnosis and treatment equipment and disposable consumables is relatively stable In 2009, the export of diagnosis and treatment equipment reached 3.77 billion US dollars, up 4.28% year on year; the import reached 5.014 billion US dollars, up 17.3% year on year The export of disposable consumables was US $1.92 billion, up 3.57% year on year; the import was US $720 million, up 19.98% year on year Affected by the financial crisis, the export of some pharmaceutical products fell Western medicine raw materials were the first to bear the brunt, with exports of US $16.56 billion, down 4.53 percentage points year-on-year, ranking first in the decline The import and export of Chinese patent medicine shrank, with the export and import down 4.23% and 3.88% respectively year-on-year; the export of health and rehabilitation products was 2.17 billion US dollars, down 4.96% year-on-year In 2009, the overall index of import and export of pharmaceutical products in China was basically the same as that in 2008, which was hard won compared with the sharp decline of national foreign trade In 2009, the import of Chinese medicine and health care products rebounded strongly, becoming the main force supporting the growth of medicine and foreign trade in 2009, showing the situation of "increase in quantity and decrease in price" In 2009, the import volume of medical and health care products increased by 3.52 billion US dollars compared with the same period of last year, but the import price fell by 9.89% while the import volume increased by 34.8% compared with the same period of last year Among them, biochemical drugs changed the most The import volume increased by 751.9% year on year, while the price fell by 84.52% In terms of import main body, high-tech value-added products such as western medicine raw materials, Western patent medicine and hospital diagnosis and treatment equipment still occupy the leading position, with the total of three items accounting for 87% of the total import On the one hand, this large-scale growth is related to the reduction of product import costs caused by the fall of the US dollar exchange rate; on the other hand, affected by the implementation of new medical reform policies in the domestic pharmaceutical market and the promulgation of favorable policies such as the "basic drug catalog" and "medical insurance catalog", the further expansion of capacity drives the rapid increase of demand 2 Export stops falling and rebounds Due to the stagnation of world economic growth, especially the sluggish demand of foreign markets and the introduction of trade protection policies by various countries, the export of Chinese pharmaceutical products fell slightly in the first 10 months of 2009 compared with the same period last year However, since November, the export has recovered from the decline, with a positive growth of 0.94% for the first time, a year-on-year growth of 3.7% in December, and a single month export of 3.576 billion US dollars Yuan, up 33.8% year-on-year and 19.2% month on month, respectively, showing a significant acceleration in the recovery The export volume of raw materials for western medicine, which accounts for more than 50% of the total export volume, increased by 6.9%, but the average price dropped by 10.7% Single month exports began to decline in the fourth quarter of 2008, and fell to the lowest level in nearly two years in February 2009 Since then, it has rebounded rapidly and stabilized, and now it has basically recovered and exceeded the level of the same period in 2008 On the year-on-year basis, after the continuous downturn in the first seven months of 2009, the growth trend in the next few months is positive On the one hand, it indicates that the overall export is stable and picking up On the other hand, it is related to the low base of export amount in the same period of 2008 The month on month trend is fluctuating, stable and fluctuating From August to December of 2009, there is a large continuous growth, decline and growth, which adds to the development of the future market Uncertainty 3 The export location pattern is relatively stable in 2009, the existing pattern of China's pharmaceutical foreign trade industry has not changed significantly, and the advantages of traditional provinces are still obvious The top five provinces and cities in terms of import and export are Shanghai, Jiangsu, Guangdong, Zhejiang and Beijing The total foreign trade volume of the five provinces and cities is 36.895 billion US dollars, accounting for 69.4% of the total foreign trade volume Among them, the import and export of Zhejiang Province fell by 1.06% year-on-year, and other provinces and cities showed a trend of growth, with the highest increase of Guangdong Province, accounting for 13.6% Jiangsu, Zhejiang, Guangdong, Shanghai and Shandong ranked the top five in terms of exports, with a total of US $22.436 billion, accounting for 68.2% of the total exports Zhejiang still ranked first in the decline list, with exports shrinking by 6.48% year-on-year to US $5.18 billion, while Guangdong's exports grew by 13.26 percentage points year-on-year to US $4.114 billion In 2009, the number of pharmaceutical foreign trade enterprises in China increased slightly, including 28389 export enterprises, 1364 more than the same period in 2008; 15486 import enterprises, 51 more than the same period in 2008 In terms of the composition of export enterprises, the number of private enterprises accounts for about 70%, and the export volume accounts for 40%; the number of "three capital" enterprises accounts for about 20%, two thirds of which are wholly foreign-owned enterprises; the number of state-owned enterprises accounts for less than 10%, but contributes nearly 20% of the export volume API manufacturing enterprises and large-scale state-owned pharmaceutical foreign trade enterprises are still the main force in the export of pharmaceutical products 4 The traditional target market remains unchanged in 2009, the share of China's pharmaceutical products in the international market remains unchanged, and the tripartite situation of Asia, Europe and North America continues to maintain, accounting for 91.4% of the share Among them, Asia continued to rank first, leading by US $19.47 billion, Europe by US $18.886 billion, and North America by US $10.22 billion Compared with the same period of 2008, China's import and export to Asia, Europe and North America increased by 11.54%, 11.4% and 4.76% year on year, respectively, reflecting the huge potential of trade with these regions It is worth noting that since March 2009, China's trade in healthcare products in Europe has turned from surplus to deficit, with a deficit of 864 million US dollars in the whole year From the perspective of export destination countries or regions, the United States, Japan, India, Germany and South Korea are the top five export destinations in China, accounting for 46.6% of China's export market share Among them, China's exports to the United States reached 6.238 billion US dollars, down 0.06% year on year Among the top 20 countries or regions, China's exports to the Netherlands, Brazil, Indonesia and other countries decreased relatively significantly compared with the same period in 2008, with a decline rate of more than 6%, while the exports to France and Vietnam showed an adverse rise with a year-on-year growth of 40.94% and 63.2%, respectively From the perspective of importing countries or regions, most of China's pharmaceutical products are imported from developed countries The top five countries are the United States, Germany, Japan, Switzerland and France The five countries together account for 52.6% of China's pharmaceutical imports Among them, the U.S import volume of US $3.56 billion firmly ranks first in China's import volume to a single country, with a year-on-year growth of 15.3%; the import volume from Switzerland rose 34% year-on-year, reaching US $1.044 billion, showing remarkable growth potential Due to the rapid growth of imports, China's pharmaceutical foreign trade with Germany, France and Belgium has a relatively high deficit, of which the deficit with Germany is 557 million US dollars, higher than that with the EU as a whole, with a year-on-year increase of 632.9%; the deficit with France is 229 million US dollars, with a year-on-year decrease of 37.4%; and the deficit with interest time is 146 million US dollars, with a year-on-year increase of 586.7% In 2009, multinational pharmaceutical companies accelerated their expansion in China The shadow of the international financial crisis continued to envelop the global market, especially the European and American markets The growth of the pharmaceutical market in developed countries such as the European and American markets was relatively slow Driven by a new round of global pharmaceutical industry transfer, multinational pharmaceutical companies are investing more and more frequently in emerging markets, and their depth and breadth are also expanding China has a huge market, rich and cheap labor force, and low-cost clinical trial resources The pharmaceutical market has been growing at an average annual rate of more than 20% for many years in a row With the implementation of the new medical reform plan, multinational pharmaceutical enterprises have significantly accelerated their expansion to China In 2009, China's pharmaceutical industry made use of foreign investment in the form of both sole investment and joint venture and cooperation At present, the number of joint ventures and wholly-owned enterprises accounts for about 30% of the total number of pharmaceutical enterprises in China, and the sales volume accounts for about 26% - 27% of the total sales volume of pharmaceutical products, which is one of the important roles in the Chinese pharmaceutical market Pfizer, MSD, Roche, GSK, Novartis, Bayer and other top 20 pharmaceutical enterprises in the world have invested and set up factories in China, many foreign-funded enterprises have also established large-scale R & D centers, and extended their tentacles to the field of drug wholesale, with a growing market share in large and medium-sized cities According to the statistics of the Ministry of Commerce, in 2009, 223 new foreign-invested enterprises were established in China's pharmaceutical industry, down 15.21% year-on-year; the actual amount of foreign investment used was US $1.111 billion, up 33.66% year-on-year Trade frictions have increased significantly since the financial crisis, many countries, due to the impact of the financial crisis, in order to protect the interests of their own enterprises, have restricted the products made in China, especially low-end pharmaceutical products, and taken trade relief measures to China has increased significantly In 2009, the trade frictions in China's pharmaceutical and health care products industry were mainly focused on the anti-dumping investigation of China's products abroad Four cases were initiated, involving disposable syringes, penicillin industrial salt and sodium gluconate The amount involved was 140 million US dollars, involving Argentina, India and the European Union Its characteristics are as follows: first, the scope of products involved in the case is expanded from APIs to medical devices In the past, more than 90% of the products that China's pharmaceutical products have been subject to foreign anti-dumping investigations are western medicine APIs Since the second half of 2008, China's disposable syringes were subject to anti-dumping investigations by Brazil and Ukraine respectively, Argentina launched another anti-dumping investigation on the same product in September 2009, involving a total amount of 4.58 million US dollars Second, the countries involved expanded from traditional markets to emerging markets In the past, the main prosecution country for pharmaceutical products was India Since 2008, some emerging markets, such as Brazil, Ukraine and Argentina, have also started to launch anti Chinese products